Sutro Biopharma, Inc. is a privately held biopharmaceutical company that is creating opportunities for the development of novel protein-based bio therapeutics using its proprietary Cell-Free protein synthesis technology. Cell-Free has the potential to overcome many of the limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. Sutro was established in 2004 and has received over $22M in funding since its inception. Major shareholders include SV Life Sciences and Alta Partners.